The estimated Net Worth of Manson Fok is at least $511 Tisíc dollars as of 3 August 2022. Manson Fok owns over 6,250 units of Athenex Inc stock worth over $405,420 and over the last 7 years he sold ATNX stock worth over $0. In addition, he makes $105,807 as Director at Athenex Inc.
Manson has made over 7 trades of the Athenex Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 6,250 units of ATNX stock worth $1,250 on 3 August 2022.
The largest trade he's ever made was buying 300,000 units of Athenex Inc stock on 19 June 2017 worth over $3,300,000. On average, Manson trades about 29,792 units every 104 days since 2017. As of 3 August 2022 he still owns at least 2,027,102 units of Athenex Inc stock.
You can see the complete history of Manson Fok stock trades at the bottom of the page.
Dr. Manson Fok serves as Director of the Company. Dr. Fok has served as a member of our Board since June 2015. Since March 2019, Dr. Fok has served as Dean of the Faculty of Medicine at Macau University of Science and Technology (MUST). From June 2013 to February 2019, Dr. Fok served as Dean, Faculty of Health Science at MUST. Dr. Fok has also served as chairman of Virtus Medical Group since January 2018. Prior to his service at MUST, beginning in October 2011 and until 2014, Dr. Fok served as the chairman of Pedder Clinic, a private medical practice in Hong Kong. He is also the Hospital Director of University Hospital at MUST; President of the Macau Healthcare Management and Promotion Association; Censor-in-Chief, World Chinese Doctors’ Association; Honorary Fellow, Chinese College of Surgeons; committee member, the Council for Medical Affairs in Macau SAR, as well as the Academy of Medicine of Macau SAR, among many other leadership positions. Dr. Fok is also a director of Avalon Biomedical (Management) Limited (“Avalon BioMedical”), an investment holding company with a focus on Asian life sciences development and commercialization. Dr. Fok was awarded the 2014 Gusi Peace Prize in Humanitarianism for his remarkable contributions to medical education, healthcare delivery and cross-border biotechnology developments that act as a bridge within Asia and across continents. From 2016 to 2018, Dr. Fok served as the president of the same Peace Prize Foundation to continue promoting peace, cooperation and healthcare development in the Asia-Pacific region. After receiving his medical degree (M.B.B.S.) from the University of Hong Kong in 1982, Dr. Fok was appointed faculty in the Surgical Unit of the University of Hong Kong. Dr. Fok has published many original research papers in high-ranking international medical journals and chapters in various academic books focusing on minimally invasive treatment for esophageal surgery.
As the Director of Athenex Inc, the total compensation of Manson Fok at Athenex Inc is $105,807. There are 14 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of $4,483,840.
Manson Fok is 63, he's been the Director of Athenex Inc since 2015. There are 8 older and 9 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
Manson's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang a Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
Athenex Inc executives and other stock owners filed with the SEC include: